89bio, Inc. Common Stock (ETNB)
89bio, Inc. (ETNB) is a biotechnology company focused on developing and commercializing targeted therapies for rare and prevalent liver diseases. Founded to address unmet medical needs, the company leverages innovative scientific approaches to create treatments that improve patient outcomes.
Company News
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involved in recent merger and acquisition transactions.
The Russell 2000 index reached an all-time high after the Federal Reserve signaled potential interest rate cuts, boosting small-cap stocks and providing cheaper borrowing opportunities for smaller companies.
89bio, a clinical-stage biotech company, reported a Q2 2025 net loss of $111.5 million, with increased R&D expenses driven by late-stage clinical trials for pegozafermin, a drug targeting metabolic and liver diseases. The company maintains substantial cash reserves of $561.2 million and continues advancing Phase 3 clinical studies.
89BIO (ETNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Madrigal Pharmaceuticals on Thursday received the FDA’s first approval of a drug designed to treat a severe liver disease known as MASH.